Trial Profile
A retrospective study investigating efficacy of switching therapy from bevacizumab or ranibizumab to aflibercept in patients with recurrent and refractory neovascular age-related macular degeneration.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 10 Feb 2016 New trial record